Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis Vaccines and Diagnostics S.r.l
Woman and Man Max 99 years
Novartis Vaccines and Diagnostics S.r.l
Update Il y a 5 ans
A Phase II, Open-label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Booster Dose of FLUAD-H5N1 (Surface Antigen Adjuvanted with MF59C.1) Influenza Vaccine in Non-elderly Adult and Elderly Subjects
1. To assess persistence of antibody titers 17-18 months after primary immunization with two 0.5mL intramuscular (IM) doses of FLUAD-H5N1 influenza vaccine containing either 7.5ᄉg or 15ᄉg of H5N1 ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Vaccines and Diagnostics S.r.l
Update Il y a 5 ans
A Phase II, Randomized, Controlled, Double-blind, Multi-center, Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 (Surface Antigen Adjuvanted with MF59C.1) Influenza Vaccines Containing 3.75 mcg or 7.5 mcg of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects
Primary To demonstrate the non-inferiority of antibody responses of two 0.5 mL intramuscular (IM) injections administered 3 weeks apart of a monovalent MF59-adjuvanted H5N1 pandemic vaccine containing...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Vaccines and Diagnostics S.r.l
Update Il y a 5 ans
A study comparing different formulations of Meningococcal C conjugate vaccine, one of which is a newly manufactured liquid formulation of the same vaccine. This study will be conducted in 12-23 months old healthy children who will be randomly vaccinated with one of vaccine formulations in healthcare institutes
The equivalence of MenC-CRM liquid to Menjugate Kit and the equivalence of MenC-CRM ROS to Menjugate Kit will be simultaneously assessed with adjustment for multiple comparisons. 1. To demonstrate th...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Vaccines and Diagnostics S.r.l
Update Il y a 5 ans
A Phase 2, Multi-Center, Open-label Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2, 6-Month Schedule and of a Single dose of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy At-risk Adults 18-50 Years of Age
Immunogenicity Objectives ᄋTo explore the immunogenicity of three doses of Novartis rMenB + OMV in healthy at risk adults, by evaluation of the breadth of serum bactericidal activity using human comp...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Vaccines and Diagnostics S.r.l
Update Il y a 5 ans
A Combined Phase II/III, Observer-Blind, Randomized, Multi-center Study to Evaluate Safety, Tolerability and Immunogenicity of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs (Fluvirin®), in Healthy Children and Adolescents Aged 3 to 17 Years
Co-Primary: To demonstrate non-inferiority of the post-vaccination (Day 50) hemagglutination inhibition (HI) geometric mean titer (GMT) of the cell culture-derived influenza vaccine to the correspond...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Vaccines and Diagnostics S.r.l
Update Il y a 5 ans
A Phase II, Open Label Study to Evaluate the Immunogenicity, Tolerability and Safety of a MF59-Adjuvanted, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects Aged 18 Years and Above
To evaluate the immunogenicity of one and two intramuscular (IM) injections of the MF59-adjuvanted H1N1sw monovalent influenza vaccine in adult and elderly subjects previously exposed to 2009/10 NH ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Vaccines and Diagnostics S.r.l
Update Il y a 5 ans
A Phase II, Observer-Blind, Randomized, Parallel Groups, Single Center, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of One and Two 0.25 mL Intramuscular Doses of FLUAD™ versus Two 0.25mL Intramuscular Doses of Vaxigrip™ Influenza Vaccines in Healthy Subjects Aged 6 to <36 Months
To evaluate the immunogenicity of one 0.25 mL intramuscular (IM) injection of FLUAD influenza vaccine and that of two 0.25 mL IM injections of the conventional influenza vaccine Vaxigrip, in terms of ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Vaccines and Diagnostics S.r.l
Update Il y a 5 ans
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUad Surface Antigen, Inactivated, Adjuvanted with MF59C.1 Influenza Vaccine, Formulation 2008-2009, when Administered to Elderly Subjects
To evaluate the antibody response to each influenza vaccine antigen, as measured by Single Radial Hemolysis (SRH) at 21 days post-immunization in non-elderly adult and elderly subjects in compliance w...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Vaccines and Diagnostics S.r.l
Update Il y a 5 ans
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year old Healthy Children who Previously Participated in Study V72P12E1 Persistencia de anticuerpos y respuesta a una tercera o quinta dosis de la vacuna meningocócica recombinante B de Novartis en niños de 4 años de edad que hayan participado previamente en el estudio V72P12E1
To explore antibody persistence in 4-year-old children after a fourth dose boost of rMenB+OMV administered at either 12, 18, or 24 months of age in study V72P12E1, in toddlers who previously received ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Vaccines and Diagnostics S.r.l
Update Il y a 5 ans
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009, when Administered to Non-elderly Adult and Elderly Subjects
To evaluate the antibody response to each influenza vaccine antigen, as measured by Single Radial Hemolysis (SRH) at 21 days post-immunization in non-elderly adult and elderly subjects in compliance w...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
Next